Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
November 16, 2017
AxoGen (AXGN) Prices offering of 2 M share at $21.00
November 14, 2017
Regenerative Medicine Earnings Scorecard - Q3/2017 to date
October 6, 2017
Biostage (BSTG) Breech, breech … breech
September 20, 2017
Juno Therapeutics (JUNO) proposes $225 M follow-on offering
June 20, 2017
Sangamo Therapeutics (SGMO) proposes $72.5 M offering
March 27, 2017
RegMed Investors’ (RMi) mid-day analysis, retracing
March 13, 2017
Fate Therapeutics (FATE) FDA clears an IND for FATE-NK100
3 hours 26 min ago
RegMed Investors’ (RMi) closing bell; just another melt down
13 hours 19 min ago
RegMed Investors’ (RMi) pre-open indications; the current sector resistance
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at firstname.lastname@example.org.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors